The trend for improved more precise diagnostics and management of disease heavily relies on the measurement of panels of biomarkers in physiological samples of patients. Ideally, the ultimate goal would be to detect as many clinically relevant biomarkers as possible in a single drop of blood, achieving quick, sensitive, reproducible, and affordable detection in small volume physiological samples. Bioluminescent (BL) proteins provide many of the desired characteristics required for such labels, including detection at extremely low concentrations, no interference from physiological fluids leading to excellent detection limits, and compatibility with many miniaturized systems. However, to date the use of BL proteins has been restricted by their limited multiplexing capabilities. BL proteins typically exhibit a single emission profile and decay kinetics making the simultaneous detection of multiple analytes difficult. Recent progresses in this area include the use of two different engineered luminescent proteins to achieve resolved signals via one-dimensional time resolution. This approach, however, to date only lead to a dual analyte detection. Herein, we have demonstrated that using a two-dimensional approach that combines both temporal and spatial resolution, we can expand the multiplexing capabilities of bioluminescent proteins. To that end, the photoprotein aequorin (AEQ) has been employed for the simultaneous detection of three separate analytes in a single well, differentiated through the use of three discrete time/wavelength windows. Through a combination of site-specific mutations and synthetic coelenterazines “semi-synthetic” AEQ variants have been developed with altered emission profiles and decay kinetics. In this study, two AEQ mutant proteins were genetically conjugated to three pro-inflammatory cytokines (tumor necrosis factor alpha, interleukins 6 and 8) resulting in AEQ-labeled cytokines. These fusion proteins were combined with synthetic coelenterazines resulting in proteins with differing emission maxima and half-lives to allow for the simultaneous detection of all three cytokines in a single sample. The validity of the assay was demonstrated in serum by employing human physiological samples and comparing our results with commercially available individual tests for each of the three cytokines.
Course-based undergraduate research experiences (CUREs) can have many positive effects on students’ learning and sense of self-efficacy. We have developed a networked CURE between four different institutions designed for courses in analytical chemistry that focuses on the process of adapting published solution-phase colorimetric assays into microfluidic paper analytical devices (μPAD) assays. We used a backward design process to develop 5 scaffolded learning outcomes: (1) identify and assess relevant literature sources, (2) propose a viable experimental plan to answer a well-defined scientific question based on literature information and experimental results, (3) apply appropriate methods of data analysis to interpret experimental results, (4) evaluate multiple pieces of experimental data to support conclusions, and (5) contribute to a team by working collaboratively toward common goals. Students begin the project by completing a literature search assignment to identify a published colorimetric assay they plan to adapt. They then write a proposal which identifies their analyte, sample of interest, and the figures of merit required for successful sample analysis using their μPAD. During the 3–5 weeks of laboratory work, students conduct their experiments, and each week evaluate the significance of their data and propose an experimental plan for the upcoming week. At the end of the μCURE project, students present their results in a joint, asynchronous poster session. Student artifacts are assessed for evidence of particular skills using rubrics from the Enhancing Learning by Improving Process Skills in STEM (ELIPSS) Project. Scores on the rubrics indicate partial to full attainment of each of the five learning outcomes.
Point-of-care (POC) diagnostics can provide early disease detection and continued monitoring for millions of people, domestically and internationally, who do not have access to essential support services. POC diagnostics can improve care and treatment decisions by shortening the time from analysis to diagnosis. Current POC diagnostic systems are limited by the availability of analyte options, nonspecific responses, the need for trained personnel, specialized instrumentation, and expensive biological components. Herein is presented a novel approach to develop POC diagnostics based on iron oxide@gold, core@shell, nanoparticles (Fe3O4@Au’s). The particles were engineered to release signaling compounds in the presence of the target analytes and built on a paper-based microfluidic (μPAD) platform to allow for inexpensive production and high portability. As a proof-of-concept, an assay for the oligonucleotide target sequence of survivin was developed. The nanoparticles were designed to release a signal in the presence of survivin DNA, which was quantified via a fluorescence signal on the μPAD platforms. The system showed selective response for the targeted survivin sequence, and detection was achieved with buffer, artificial saliva, artificial urine, and human serum matrices.